Price Alert

Arcus Biosciences Inc. (RCUS)

NYSE: RCUS · Real-Time Price · USD

10.46

0.55 (5.55%)

At close: Aug 15, 2025, 1:22 PM

Arcus Biosciences Statistics

Share Statistics

Arcus Biosciences has 106.43M shares outstanding. The number of shares has increased by 15.81% in one year.

Shares Outstanding	106.43M
Shares Change (YoY)	15.81%
Shares Change (QoQ)	0.04%
Owned by Institutions (%)	98.75%
Shares Floating	64.97M
Failed to Deliver (FTD) Shares	10,129
FTD / Avg. Volume	1.01%

Short Selling Information

The latest short interest is 10.05M, so 9.5% of the outstanding shares have been sold short.

Short Interest	10.05M
Short % of Shares Out	9.5%
Short % of Float	14.56%
Short Ratio (days to cover)	13.06

Valuation Ratios

The PE ratio is -4.74 and the forward PE ratio is -2.02. Arcus Biosciences's PEG ratio is 0.19.

PE Ratio	-4.74
Forward PE	-2.02
PS Ratio	5.2
Forward PS	6.7
PB Ratio	2.77
P/FCF Ratio	-7.62
PEG Ratio	0.19

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Arcus Biosciences.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.5, with a Debt / Equity ratio of 0.12.

Current Ratio	4.5
Quick Ratio	4.5
Debt / Equity	0.12
Debt / EBITDA	-0.22
Debt / FCF	-0.34
Interest Coverage	-82.5

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$411.48K
Profits Per Employee	$-451.36K
Employee Count	627
Asset Turnover	0.22
Inventory Turnover	n/a

Taxes

Income Tax	-1M
Effective Tax Rate	0.35%

Stock Price Statistics

The stock price has increased by -38.66% in the last 52 weeks. The beta is 0.89, so Arcus Biosciences's price volatility has been higher than the market average.

Beta	0.89
52-Week Price Change	-38.66%
50-Day Moving Average	9.18
200-Day Moving Average	11.44
Relative Strength Index (RSI)	46.4
Average Volume (20 Days)	1,002,761

Income Statement

In the last 12 months, Arcus Biosciences had revenue of 258M and earned -283M in profits. Earnings per share was -3.14.

Revenue	258M
Gross Profit	258M
Operating Income	-330M
Net Income	-283M
EBITDA	-268M
EBIT	-279M
Earnings Per Share (EPS)	-3.14

Full Income Statement

Balance Sheet

The company has 150M in cash and 60M in debt, giving a net cash position of 90M.

Cash & Cash Equivalents	150M
Total Debt	60M
Net Cash	90M
Retained Earnings	-1.13B
Total Assets	1.07B
Working Capital	736M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -170M and capital expenditures -6M, giving a free cash flow of -176M.

Operating Cash Flow	-170M
Capital Expenditures	-6M
Free Cash Flow	-176M
FCF Per Share	-1.95

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -127.91% and -109.69%.

Gross Margin	100%
Operating Margin	-127.91%
Pretax Margin	-109.69%
Profit Margin	-109.69%
EBITDA Margin	-103.88%
EBIT Margin	-127.91%
FCF Margin	-68.22%

Dividends & Yields

RCUS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for RCUS is $22, which is 139.9% higher than the current price. The consensus rating is "Buy".

Price Target	$22
Price Target Difference	139.9%
Analyst Consensus	Buy
Analyst Count	8

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-0.38
Piotroski F-Score	1